{"id":63832,"date":"2025-01-22T00:01:28","date_gmt":"2025-01-22T00:01:28","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2025\/01\/22\/adagene-to-announce-updated-data-from-phase-1b-2-study-of-muzastotug-in-combination-with-keytruda-pembrolizumab-in-colorectal-cancer-at-asco-gastrointestinal-cancers-symposium\/"},"modified":"2025-01-22T00:01:28","modified_gmt":"2025-01-22T00:01:28","slug":"adagene-to-announce-updated-data-from-phase-1b-2-study-of-muzastotug-in-combination-with-keytruda-pembrolizumab-in-colorectal-cancer-at-asco-gastrointestinal-cancers-symposium","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/adagene-to-announce-updated-data-from-phase-1b-2-study-of-muzastotug-in-combination-with-keytruda-pembrolizumab-in-colorectal-cancer-at-asco-gastrointestinal-cancers-symposium\/","title":{"rendered":"Adagene to Announce Updated Data from Phase 1b\/2 Study of Muzastotug in Combination with KEYTRUDA\u00ae (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium"},"content":{"rendered":"<div>\n<p align=\"left\">SAN DIEGO and SUZHOU, China, Jan.  21, 2025  (GLOBE NEWSWIRE) &#8212; Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced it will share updated clinical data from ADG126 in microsatellite stable colorectal cancer (MSS CRC) at the ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA on Saturday, January 25, 2025.<\/p>\n<p>This Phase 1b\/2, open-label, multicenter dose escalation and expansion combination study of ADG126 in combination with Merck\u2019s (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab; 200 mg, Q3W) in MSS CRC previously demonstrated efficacy at the 10 mg\/kg Q3W dose.<\/p>\n<p>New data will include initial results from the 20 mg\/kg loading dose followed by 10 mg\/kg Q3W in combination with pembrolizumab.<\/p>\n<p><strong>ASCO-GI Poster Presentation Details<\/strong><\/p>\n<p>Title: Update of phase 1b\/2 study of muzastotug (ADG126, an anti-CTLA-4 SAFEbody) in combination with pembrolizumab in advanced\/metastatic MSS CRC<\/p>\n<p>Date: Saturday, January 25<\/p>\n<p>Time: 7:00 a.m. \u2013 7:55 a.m. Pacific Time<\/p>\n<p>Onsite Location: Moscone West, San Francisco<\/p>\n<p>Abstract Number: 193<\/p>\n<p>Poster Board: H5<\/p>\n<p>Following the presentation, the poster will also be available on the Publications page of the Company\u2019s website.<\/p>\n<p><strong>Virtual KOL Event to Discuss Anti-CTLA-4 SAFEbody<\/strong><sup><strong>\u00ae<\/strong><\/sup><strong> ADG126 in Advanced\/Metastatic Microsatellite-Stable (MSS) Colorectal Cancer (CRC) on January 25, 2025<\/strong><\/p>\n<p>Company will host a virtual key opinion leader (KOL) event on Saturday, January 25, 2025 at 1:00 PM ET, featuring Aur\u00e9lien Marabelle, MD, PhD (Universit\u00e9 Paris-Saclay), Daneng Li, MD (City of Hope), and Marwan Fakih, MD (City of Hope), who will join company management to discuss the unmet need and current treatment landscape for patients with advanced\/metastatic microsatellite-stable (MSS) colorectal cancer (CRC) and why CTLA-4 targeting is essential for achieving durable responses in this cold tumor type. To register, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jaL8w9Eb_XTjgZVUGYbqylCanX69yQD5THY7fO5BIjzBumP6spV9PrTJOQo5YFKidzTfYRB07x5L4UxKUC2pFblEurfPZ9UH2gH8Rp3LGvQ=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>click here.<\/u><\/a><\/p>\n<p><strong>About\u00a0Adagene<\/strong><br \/>Adagene Inc.\u00a0(Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene\u00a0combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody<sup>\u00ae<\/sup>\u00a0precision masking technology in multiple approaches at the vanguard of science.<\/p>\n<p>Powered by its proprietary\u00a0Dynamic Precision Library\u00a0(DPL) platform, composed of NEObody&#x2122;, SAFEbody, and POWERbody&#x2122; technologies, Adagene\u2019s highly differentiated pipeline features novel immunotherapy programs. The company\u2019s SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies in tumor microenvironment, while minimizing on-target off-tumor toxicity in healthy tissues.<\/p>\n<p>Adagene\u2019s lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment. ADG126 is currently in phase 1b\/2 clinical studies in combination with anti-PD-1 therapy, particularly focused on Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC). Validated by ongoing clinical research, the SAFEbody platform can be applied to a wide variety of antibody-based therapeutic modalities, including Fc empowered antibodies, antibody-drug conjugates, and bi\/multispecific T-cell engagers.<\/p>\n<p>For more information, please visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RAUdGkoow9-OA77wdkU6TKrUhlmWPWPHJsSz3bkQ_eELji2-Vv4apct5KhErxMKlYphe98ae_CJM9GWYLZdjsajZKWT_oTBYr_3hYQL_eYuF86wOFBkLnrjMB_0WjSlBuP_MmwDvJkt3h_MQpJD1UREBdhnodSlWVTd7xKof8FcC85-YfUS9uaryEWYCSrfUERaPONx5ERxVHUqgqB8a68h80ASKqSLhtJoUYpSZFFQGJecVY17Dvy7aOy1MllYQhiPg4j8mWdoK-pSxnqzcr_Gx2JIXqfPaWSA6kJUTkoh4ZbOszrWwJfCfVuR3f-FU4XLRbi6w4rUcdg8mg6uJj8GUu0DP0Wiq8cs1kogxgGwgmFnHTX9wkQV5GlGflAaD5O4qkTs1jGKb9LxvEdSYdR2rtHXSigXG46TiEoEhAOfKICnmk0zwEdBpkpZ38GprtJTtiJuN45ug01qSYXO_T3Aw0Mn-dAMybfbrQupthtnbPIPgTe9G9kt90qS8MHWvcMqfbQXPw8pFJgqr-whLZlDSUn0242KzEXUyjeUu7nWkP9LjRogsKrdcucc-GdNlWli6mT5bGB8Xfdv4ctzpSQUmTJcL208afsiaE1pzKw2K0tGYYk-A9dcPilhIHtFf6hOvKUN2G--Vkdp8dsAV03upHTmb-QP1TqXJ9dcXpfbfWSgCgb46UAj43mSosYFLrmJPsdTIMWsWhEZXlMrRV-6sNLqRF18sLuk4gWUaSyuVIBKU-PC-GvS4zw8yFTKGj_8sg-FJHwK0IK48burrF4fOu6I5zpZwYQSvdp6tE7SWCcfrXGUtWE8iCWaMfF9qIZSQtEexnpGH4EvSL9RZILrnRPLybvno51Mh8zO-n_YdxDTxzu_BWoJZCN1Jl6P9LAxZizgqJ1LgZpivgzQoKzYRNIQ9imbpZenPzRYZmoRvrhL5s43-KOxBqcIj_Xh1jXseY06615P0ysb4NnHcCTODSqjHYwyNz4urw-QnOx7GHopU2PuttrdRp0RrlymAqg4F6VykZx8wm7n2kRgHizMC4GK7xabOSqYtDnliXKYodcnmtbZvqZZTtH11ZMnEb_gQ365dfgU25lMJIoFzvp_ZfydgyDyyVxt9t2Vyhpb6dc6x7N-1wzuohbPN6eMimKbMGNfmM7twbkNzD73KX8rirvm0mccKFFKprCtp9lR0FC9TC-cCic6Wm8K66jgz_9gATD0mUPVJDk22XHFyErI9kd5acE_FObvRuYjZoXi3y7tJmBIuguPdXLYIFEuBex9SQxbl4y6oQkih1wSILYm3MZ5mZSpsBl5aevfooi89uH2DtEaNLUgcoJorWswY4NcwaakM9_FhnXMtkjTB6PXNeMGPN2eiXmXNN4Yl9E2BIohywh46xj6T55tszdGixriJl6qHykroWiq1MrfUXK_2pK2sKMWv0c90rcvx7arKwSPdUo0u-lSe46ljKiPwaO4dgJEn7uEtxoiZdbVk8MWsS48SFB_c44_wUZuMtqvHyAvMRChE76-9X-qHc06bxHmRN8eJuE_hnGjlzzQnMkKuJCCouEi-wICFhUt_tfmiw7fXllE5aaZJVaWt6gtDSwmWaARVSKS5xtvR7dKU-uI99LViqt7z8VQgQWq1G1_3MszzH7HqZwtY-VOf4torYJNILhrMpVVXEDvYpc0L9Ejc2aQnUlGUigYguQ4a-zXRVuOMyPR0TX_6zTed8V5qId2tU44HqoF_iaawHlA2CA==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/investor.adagene.com<\/a>.<br \/>Follow\u00a0Adagene\u00a0on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3TOmeQWBzdrRkUGkekWzGYltJ3Zqpn6aM1lCTbZOMfCmZKSWtgHDYxZXFtZamXUd46oNMQlRgWKtBVVKPf4bYQunpPyRYWB21zh0IUkgKWAH0rw71mw3ggxXoG8FTKIH6vbBPJaM1wzdKEUtkS5moum0Uuh8LZMYWxaOsQwQrHSOnudteK144AAZZ02EpIkWTlke8PwQpmP2Iqpq4xmIcotcn57myR71RuaPWVWciikQyn5DKvhwtqJcKNqlgsLU8em29z98D_Jav-n407u65tjeVkiNsZv8iCxRVb1JcP_Oy-g5TNFKhw1I4MQ3a_bgutzFEtgCeNxTRcLsXK1gQQHqvHFD-bX7ZSYIQkOYn13wFY7N5z58PXrmEtiEmd-8s6ASl9xXF_kENMrurIpyAyndSYG-b-bFjzx0a27DHSKYp2VImChGItBS6yiKrfkPZMiLrrnrPMFIz5spa-IsbKMFgtSwRdbFp6wH7LTM7J10jVKWpAAMJma81pQ5lHixAxDUZoEnSnkVP9pwrJ3NJdxz60_K2xox_vwu6q_7DiTeFkaGlU5I3HC3JMucDT-pVkCRHuamrmvV3X7TImlKWTWC0e0vzmBZB292fRndz_WPwRauso14plAppmjOa1sTLRzvpkbwC8GBfFQ8-JDLUTybIebga_zqNzy3tVu9Q6ym0Y6FC9Gq7P9AUkgKPTWehRD9gv074u6g0-I7G-fKhlKuzwZdpLrw1Ch-Pi_UVamqZwiJFQj444OvucLcZ_2Px2oW9JhdIQV0z4PtYVP6DmThehElcnt6C_mLyTtGgvRU5RQ4GB-4LD_Gf3hMjLwgGnoAOwkpQCRknvx-N_8urIEVi-66svzgGy51j3EpBTc2Lvgxie6r3Z8fmUHpsBjnKDrH4TqF8ud9mCLhJtuYwuhfL64RyZDhaIRtlpGTf6k_ZEl2Nhws5LKpHm_pBGoDp_YdHLt1MoESITf-YMMULsWgesTNVpXYaDG_WyhnwTPwmU5N5-aLagghrHoXsOWLtmh_3x_fEp_zrRu2aYO1IuQWWz84yD8z9ZUfbAWCFUwd2ijlL7sVHQqQSm7t8xIe5jiaI2npA-l4DqAmvsIBB5UcqLY2vNFxC673-RSQ7Fqgf86_7apksNlB8bva0ccAR3y-AOqmipBMrEM1DKCRWqSSACsBNOC7RVc0qwPF1E1voqYPjViuJITgOtkXX6MOpRzyoc7A5mdi0KNwhe9--3WqlElpYfE5Ko4tX3Tnu2y_pxTlLIYMlvVg1qXzYTXJVCUO8S2sO-QbEXX_xusXQ4nbiJpPEQOQuRU3sB3hJSnFVl1uisjR0vRR9NaIaFNXwmi5B_gqd-dydBf2vOwdEs0-mpXloXU_APkJvYX27KXTQFgHnJBjBJxm_iCs4MLddKrD73ijGvw_g1pL78t8Gflp_0720EZhm2CUPXgCnl56mP14TiqySIkLIxdYQ23DnM_ZDYa7Tk2qUBUvLsVpLzOM54RsdGUkktiQNNFNBA1y4QS6vooeWrOpeS93EZgUcNbCZYMgiMULQLJsw1gmKUTuZeHry8QFt72UFqOmXJ_Wq6_wJEmPNP2sxDFRsRfdhHfyHAjdxGHMgsipSliMBsA0AK17lCK0_jlDaWUxbXZ0l0slpixneK-f0Bufs1lck2xe5tousy8pkmPlDLybSRu_V3DGbXFF3aaroLm1kzhvk5HiDIArB46_tRBIPgKh-8ktElHvF0WNqvyExdJRNe71uXRJVktEO_9y2VMhDMZxmJ-3NeLYLcLkJd3CucqtpIBXxY6oFLziB8hECAw6hFwL-EnjoilFV0OAjezNHjWuN0LBU1g-BxTbuaQo-_A3TDrJL7PQ68USM1Lwdd-yg5kuTsUrjOW-O2Ov-1l3oXA=\" rel=\"nofollow\" target=\"_blank\" title=\"WeChat\">WeChat<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MvecftvFbK4-xaPjPJgukJ8p7wFRYpRuYVRQ3hV78cVp3VnvHZAyClf85mqiTGIZdlHC4KBFheTI-l4DbYhlNU4Ox3y54ijHp93wdYbblgyMMIoa72D9uGJo0uOdKenJ-HsnrZbdjKp2-JGTH0hGzfvDnBBUpylcdaiZn6Yvo-NGvkpoLB3nGqYEH1TKYWeN-ELTJXFPry12jECaoUfrX6tc4yIKwUBjr9sabtDdeVFriln6b2i2EE-qskJhPFpas2EwexYxkyBvcrhhOrAfDgv5dkS9NXjCrxAzDhbg-ao0pwVU7v38VJMn2bYvrlFpaTqZk76WPUrSbOkM051plw1Mfk4Z4YS8ls1MclXNjVXwUcH8VTvPActkFq_ljpWYZ3ZjehZw9yXQtnh8fdwmXJd4sJseyo2i3bcbGRIBw8L5xYp9kLgzrA7dD8f8jvyrbWi5eradk4FOPsyrXDD-cUEMc-AQ0P5y85gc9TlQPB9bBx6ZDSnumuwn_x0-AbJLVusKv75fjqR6kra5jG9e--VGyqUGPYlTRBh6ODbsAPlC87ir2e045KUfBCm5RcPknTRmN5gZmsL3T0abJOLd_UGUHYKPgx_fbipZuQrc5eZ_wZkhgj0X-qVx0JnPRJUjliFNCcOFuJBvoXwUPexvj6_G9szUtfA8TOCD92pJA30o3E0z3_ao6mvJngk0FV-2p1fqlyLQGG7ihPejdS3Kqusw7TKArIiZL6cM0hY8kACzr2z4xXx96zws1IXK6WD50KZ2QB4Ss7YGyeCVP_UpAp58NOlElYXnXSuniUnz4uX9ARs7GnSEZb5ypQkgrjHcbMNxSZodGRiT_5fNgbcY8ZwH8VusLOc2XV9yX8T81jaFfXBaf8IPfrrNjTZDRW5xNeG-1mn6zIX9r1Pe02Yj5q5CLdsE16TGY_UgwYqCGYxzQ_4-AG8s82hoG5SlszoRSb3p8ol3QC5SHgo59qH1WqPMy6qNC74QkwC4talymNIO1G6mUx3ZCAhmirTdixwnJikgRtmXakxLdMNS7j-Mrg==\" rel=\"nofollow\" target=\"_blank\" title=\"LinkedIn\">LinkedIn<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=W33LfWNbDb_99329xlMTSTH1a-pWGN2ki5d4_X7rYUJN_ZD6zXa1b3yIN9yL3IGzMHJoBjDhZLt2rlFwIFOaLmlkPIGp6fcDDKqqVLqwEJFre6Lt3Y1zrtnNhq7Jbbn6D0Owt5vEx-CUHFFZOXWEKfEuxlUithDJJmgciu0looQAfyNGRUEBC_CT8N3pSXsojH03cj6Ryp7Ya1k-BwXLU1HPjLhl6Pmhz2boRJ_bUd6SvBlJppxglpGhSq74QHajnebx2MqSWtr8OgleSNOoI_AqpMo9cfiF0O7InSJxNSb0cFmkbEGcfJ6zSW4lQ1hwRcO4_SNPYfxqj9qKsRucMVFUPP16hsjoL1i0al8dbPY77Wi64V6sepKtBlHYr6Wr3RO3w6mAb1ckL_ZL9aXKqq-SyJ9TfeFEfVODnqrRvt7xjm0vMtKK_eZ6Wv8EjByisBZQhPuFjpf-cSKbVs8NrKKNVkpgfJUYHuekdf2l1oPA6d2vrJRrezZpRMCdGM2uueX1cL8p6yCzx17tnHtTNIC5m6-S5rdrPFQ9i9obFWoCFCHxm5cH_AgC7FGwo--2vi1CTIozgIBv6HHrqR8cmkN9wdaEBcoLFnT06Y8x5SuMtlX2i5bqHh4EVLj6p9censjU2P1NUk_tgg9cBoEjgRX5SnV4DHQlv8cFtWkMomZkw6acRr3Vepvb4YuMapc9KvrgDZCmMrYHw5Syjt7vTKQy4ZRMcP0bptNCJc2JprHzOq82qAQEgko11SoHGuC5JiYoveoOwhiByoHKsdutPvV8dPFHD3CQGdopgeGS_itEbqv_Rts_nlItaEDnMszdUAaK-rBpk1AS4cpawD0ZNrsBxn97oCoSSUTGcuCPaLxRBd68Opy7OEtt9ZVQI8NVp1WxgRinsHXC7rBgPg8J1UvlGj5JHOiuKEKWB2TwiR5fuAgFtAAKB0PcdbnEUBt2C7gxL-6azYCLUMMw6yxqhu9igYwN0WS4sIq_9VVhCs2uYHKn1QeAdWEqx_yGYXU0\" rel=\"nofollow\" target=\"_blank\" title=\"Twitter\">Twitter<\/a>.<\/p>\n<p>SAFEbody<sup>\u00ae<\/sup>\u00a0is a registered trademark in\u00a0the United States, China, Australia, Japan, Singapore, and the European Union.<\/p>\n<p>KEYTRUDA<sup>\u00ae<\/sup> is a registered trademark of\u00a0Merck Sharp &amp; Dohme LLC, a subsidiary of Merck &amp; Co., Inc.,\u00a0Rahway, NJ, USA.<\/p>\n<p><strong>Safe Harbor Statement<\/strong><br \/>This press release contains forward-looking statements, including statements regarding certain clinical results of ADG126, the potential implications of clinical data for patients, and Adagene\u2019s advancement of, and anticipated preclinical activities, clinical development, regulatory milestones, and commercialization of its product candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Adagene\u2019s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Adagene\u2019s drug candidates; Adagene\u2019s ability to achieve commercial success for its drug candidates, if approved; Adagene\u2019s ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene\u2019s reliance on third parties to conduct drug development, manufacturing and other services; Adagene\u2019s limited operating history and Adagene\u2019s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene\u2019s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations, and the impact of the COVID-19 pandemic on Adagene\u2019s clinical development, commercial and other operations, as well as those risks more fully discussed in the \u201cRisk Factors\u201d section in Adagene\u2019s filings with the\u00a0U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to\u00a0Adagene, and\u00a0Adagene\u00a0undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.<\/p>\n<p><strong>Investor Contact:<\/strong><\/p>\n<p>Bruce Mackle<br \/>LifeSci Advisors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AW_f7kMhvOj_j1Gus4OwV5yae4wHEhruYELE71Z9fQ8xwgj06t-bpdlW805l9yMEgPxe9GtoQ2aP0PWItVtWw3t9ZsXAFOPWzJBAv5Y11ZL2RGmMPA1O8n36_LAQWFnJ\" rel=\"nofollow\" target=\"_blank\" title=\"bmackle@lifesciadvisors.com\">bmackle@lifesciadvisors.com<\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OTg1MjdmMDYtODZjOS00MGI2LWE1NTEtNzc5NjYyZDYwODM5LTEyMTYyMzQ=\/tiny\/Adagene-Inc-.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO and SUZHOU, China, Jan. 21, 2025 (GLOBE NEWSWIRE) &#8212; Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced it will share updated clinical data from ADG126 in microsatellite stable colorectal cancer (MSS CRC) at the ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA [&#8230;]\n","protected":false},"author":1,"featured_media":63833,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-63832","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Adagene to Announce Updated Data from Phase 1b\/2 Study of Muzastotug in Combination with KEYTRUDA\u00ae (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/adagene-to-announce-updated-data-from-phase-1b-2-study-of-muzastotug-in-combination-with-keytruda-pembrolizumab-in-colorectal-cancer-at-asco-gastrointestinal-cancers-symposium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adagene to Announce Updated Data from Phase 1b\/2 Study of Muzastotug in Combination with KEYTRUDA\u00ae (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO and SUZHOU, China, Jan. 21, 2025 (GLOBE NEWSWIRE) &#8212; Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a company transforming the discovery\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/adagene-to-announce-updated-data-from-phase-1b-2-study-of-muzastotug-in-combination-with-keytruda-pembrolizumab-in-colorectal-cancer-at-asco-gastrointestinal-cancers-symposium\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-22T00:01:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2025\/01\/Adagene-Inc-.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/adagene-to-announce-updated-data-from-phase-1b-2-study-of-muzastotug-in-combination-with-keytruda-pembrolizumab-in-colorectal-cancer-at-asco-gastrointestinal-cancers-symposium\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/adagene-to-announce-updated-data-from-phase-1b-2-study-of-muzastotug-in-combination-with-keytruda-pembrolizumab-in-colorectal-cancer-at-asco-gastrointestinal-cancers-symposium\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Adagene to Announce Updated Data from Phase 1b\/2 Study of Muzastotug in Combination with KEYTRUDA\u00ae (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium\",\"datePublished\":\"2025-01-22T00:01:28+00:00\",\"dateModified\":\"2025-01-22T00:01:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/adagene-to-announce-updated-data-from-phase-1b-2-study-of-muzastotug-in-combination-with-keytruda-pembrolizumab-in-colorectal-cancer-at-asco-gastrointestinal-cancers-symposium\/\"},\"wordCount\":887,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/adagene-to-announce-updated-data-from-phase-1b-2-study-of-muzastotug-in-combination-with-keytruda-pembrolizumab-in-colorectal-cancer-at-asco-gastrointestinal-cancers-symposium\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/adagene-to-announce-updated-data-from-phase-1b-2-study-of-muzastotug-in-combination-with-keytruda-pembrolizumab-in-colorectal-cancer-at-asco-gastrointestinal-cancers-symposium\/\",\"name\":\"Adagene to Announce Updated Data from Phase 1b\/2 Study of Muzastotug in Combination with KEYTRUDA\u00ae (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2025-01-22T00:01:28+00:00\",\"dateModified\":\"2025-01-22T00:01:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/adagene-to-announce-updated-data-from-phase-1b-2-study-of-muzastotug-in-combination-with-keytruda-pembrolizumab-in-colorectal-cancer-at-asco-gastrointestinal-cancers-symposium\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/adagene-to-announce-updated-data-from-phase-1b-2-study-of-muzastotug-in-combination-with-keytruda-pembrolizumab-in-colorectal-cancer-at-asco-gastrointestinal-cancers-symposium\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/adagene-to-announce-updated-data-from-phase-1b-2-study-of-muzastotug-in-combination-with-keytruda-pembrolizumab-in-colorectal-cancer-at-asco-gastrointestinal-cancers-symposium\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Adagene to Announce Updated Data from Phase 1b\/2 Study of Muzastotug in Combination with KEYTRUDA\u00ae (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Adagene to Announce Updated Data from Phase 1b\/2 Study of Muzastotug in Combination with KEYTRUDA\u00ae (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/adagene-to-announce-updated-data-from-phase-1b-2-study-of-muzastotug-in-combination-with-keytruda-pembrolizumab-in-colorectal-cancer-at-asco-gastrointestinal-cancers-symposium\/","og_locale":"en_US","og_type":"article","og_title":"Adagene to Announce Updated Data from Phase 1b\/2 Study of Muzastotug in Combination with KEYTRUDA\u00ae (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium","og_description":"SAN DIEGO and SUZHOU, China, Jan. 21, 2025 (GLOBE NEWSWIRE) &#8212; Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a company transforming the discovery","og_url":"https:\/\/english.saigonbiz.com\/vn\/adagene-to-announce-updated-data-from-phase-1b-2-study-of-muzastotug-in-combination-with-keytruda-pembrolizumab-in-colorectal-cancer-at-asco-gastrointestinal-cancers-symposium\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2025-01-22T00:01:28+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2025\/01\/Adagene-Inc-.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/adagene-to-announce-updated-data-from-phase-1b-2-study-of-muzastotug-in-combination-with-keytruda-pembrolizumab-in-colorectal-cancer-at-asco-gastrointestinal-cancers-symposium\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/adagene-to-announce-updated-data-from-phase-1b-2-study-of-muzastotug-in-combination-with-keytruda-pembrolizumab-in-colorectal-cancer-at-asco-gastrointestinal-cancers-symposium\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Adagene to Announce Updated Data from Phase 1b\/2 Study of Muzastotug in Combination with KEYTRUDA\u00ae (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium","datePublished":"2025-01-22T00:01:28+00:00","dateModified":"2025-01-22T00:01:28+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/adagene-to-announce-updated-data-from-phase-1b-2-study-of-muzastotug-in-combination-with-keytruda-pembrolizumab-in-colorectal-cancer-at-asco-gastrointestinal-cancers-symposium\/"},"wordCount":887,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/adagene-to-announce-updated-data-from-phase-1b-2-study-of-muzastotug-in-combination-with-keytruda-pembrolizumab-in-colorectal-cancer-at-asco-gastrointestinal-cancers-symposium\/","url":"https:\/\/english.saigonbiz.com\/vn\/adagene-to-announce-updated-data-from-phase-1b-2-study-of-muzastotug-in-combination-with-keytruda-pembrolizumab-in-colorectal-cancer-at-asco-gastrointestinal-cancers-symposium\/","name":"Adagene to Announce Updated Data from Phase 1b\/2 Study of Muzastotug in Combination with KEYTRUDA\u00ae (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2025-01-22T00:01:28+00:00","dateModified":"2025-01-22T00:01:28+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/adagene-to-announce-updated-data-from-phase-1b-2-study-of-muzastotug-in-combination-with-keytruda-pembrolizumab-in-colorectal-cancer-at-asco-gastrointestinal-cancers-symposium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/adagene-to-announce-updated-data-from-phase-1b-2-study-of-muzastotug-in-combination-with-keytruda-pembrolizumab-in-colorectal-cancer-at-asco-gastrointestinal-cancers-symposium\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/adagene-to-announce-updated-data-from-phase-1b-2-study-of-muzastotug-in-combination-with-keytruda-pembrolizumab-in-colorectal-cancer-at-asco-gastrointestinal-cancers-symposium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Adagene to Announce Updated Data from Phase 1b\/2 Study of Muzastotug in Combination with KEYTRUDA\u00ae (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/63832","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=63832"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/63832\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/63833"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=63832"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=63832"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=63832"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}